Antibody Fc Engineering: Towards Better Therapeutics
Monoclonal antibodies and Fc-fusion proteins used clinically are Fc-based therapeutics that grow fastest in the pharmaceutical industry. Since they both contain an Fc fragment, engineering of Fc fragments could be a platform for improving Fc-based drug efficacy. Fc engineering includes various aspec...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Online |
| 言語: | 英語 |
| 出版事項: |
Frontiers Media SA
2021
|
| 主題: | |
| オンライン･アクセス: | 32062 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
| _version_ | 1869514762514071552 |
|---|---|
| author | Rui Gong Tianlei Ying |
| author_browse | Rui Gong Tianlei Ying |
| author_facet | Rui Gong Tianlei Ying |
| author_sort | Rui Gong |
| collection | Directory of Open Access Books |
| description | Monoclonal antibodies and Fc-fusion proteins used clinically are Fc-based therapeutics that grow fastest in the pharmaceutical industry. Since they both contain an Fc fragment, engineering of Fc fragments could be a platform for improving Fc-based drug efficacy. Fc engineering includes various aspects: stabilization of Fc; regulation of effector functions including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity; extension of serum half-life by modification of neonatal Fc receptor (FcRn) binding; monomerization or heterodimerization of Fc for design of new Fc formats. Currently, many new methods are being used in Fc engineering. Compared to traditional methods such as site mutagenesis on certain positions by amino acid replacement, new methods such as display-based technology can confer high throughput screening and obtain optimized variants relatively quickly, accelerating the drug development process. With the new methods, many new Fc variants were identified. On this Research Topic we are going to review the progress in current Fc engineering including the new engineering methods and the Fc variants or constructs they have produced, and the potential of these new Fcs in clinical use. |
| format | Online |
| id | doab-20.500.12854ir-40953 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-409532024-03-30T23:21:40Z Antibody Fc Engineering: Towards Better Therapeutics Rui Gong Tianlei Ying R5-920 RC581-607 effector function Fc receptor heterodimeric Fc Fc-fusion protein monomeric Fc Monoclonal antibody Fc engineering thema EDItEUR::M Medicine and Nursing Monoclonal antibodies and Fc-fusion proteins used clinically are Fc-based therapeutics that grow fastest in the pharmaceutical industry. Since they both contain an Fc fragment, engineering of Fc fragments could be a platform for improving Fc-based drug efficacy. Fc engineering includes various aspects: stabilization of Fc; regulation of effector functions including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity; extension of serum half-life by modification of neonatal Fc receptor (FcRn) binding; monomerization or heterodimerization of Fc for design of new Fc formats. Currently, many new methods are being used in Fc engineering. Compared to traditional methods such as site mutagenesis on certain positions by amino acid replacement, new methods such as display-based technology can confer high throughput screening and obtain optimized variants relatively quickly, accelerating the drug development process. With the new methods, many new Fc variants were identified. On this Research Topic we are going to review the progress in current Fc engineering including the new engineering methods and the Fc variants or constructs they have produced, and the potential of these new Fcs in clinical use. 2021-02-11T08:14:50Z 2021-02-11T08:14:50Z 2019-01-23 14:53:43 2018 book 32062 16648714 9782889456789 https://directory.doabooks.org/handle/20.500.12854/40953 eng Frontiers Research Topics image/jpeg Attribution 4.0 International https://www.frontiersin.org/research-topics/4342/antibody-fc-engineering-towards-better-therapeutics Frontiers Media SA 10.3389/978-2-88945-678-9 10.3389/978-2-88945-678-9 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889456789 118 open access |
| spellingShingle | R5-920 RC581-607 effector function Fc receptor heterodimeric Fc Fc-fusion protein monomeric Fc Monoclonal antibody Fc engineering thema EDItEUR::M Medicine and Nursing Rui Gong Tianlei Ying Antibody Fc Engineering: Towards Better Therapeutics |
| title | Antibody Fc Engineering: Towards Better Therapeutics |
| title_full | Antibody Fc Engineering: Towards Better Therapeutics |
| title_fullStr | Antibody Fc Engineering: Towards Better Therapeutics |
| title_full_unstemmed | Antibody Fc Engineering: Towards Better Therapeutics |
| title_short | Antibody Fc Engineering: Towards Better Therapeutics |
| title_sort | antibody fc engineering towards better therapeutics |
| topic | R5-920 RC581-607 effector function Fc receptor heterodimeric Fc Fc-fusion protein monomeric Fc Monoclonal antibody Fc engineering thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RC581-607 effector function Fc receptor heterodimeric Fc Fc-fusion protein monomeric Fc Monoclonal antibody Fc engineering thema EDItEUR::M Medicine and Nursing |
| url | 32062 |
| work_keys_str_mv | AT ruigong antibodyfcengineeringtowardsbettertherapeutics AT tianleiying antibodyfcengineeringtowardsbettertherapeutics |